NcXHF

ABBAS MANJI ET AL
versus doxorubicin plus ifosfamide in fırst-line treatment of advanced
soft tissue sarcomas: a randomized study of the European Organization
for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma
Group. J Clin Oncol. 1995;13:1537-1545.
3. Ng VC, Scharschmidt TJ, Mayerson JL, et al. Incidence and survival in
sarcoma in the United States: a focus on musculoskeletal lesions. Anticancer
Res. 2013;33:2597-2604.
4. Fletcher CDM, Bridge JA, Hogendoorn PCW, et al. World Health Organization
Classifıcation of Tumors of Soft Tissue and Bone, 4th ed. Lyon: IARC
Press; 2013.
5. Conyers R, Young S, Thomas DM. Liposarcoma: molecular genetics
and therapeutics. Sarcoma. 2011;2011:483154.
6. Crago AM, Singer S. Clinical and molecular approaches to well differentiated
and dedifferentiated liposarcoma. Curr Opin Oncol. 2011;23:373-378.
7. Singer S, Socci ND, Ambrosini G, et al. Gene expression profıling of
liposarcoma identifıes distinct biological types/subtypes and potential
therapeutic targets in well-differentiated and dedifferentiated liposarcoma.
Cancer Res. 2007;67:6626-6636.
8. Lahat G, Tuvin D, Wei C, et al. New perspectives for staging and prognosis
in soft tissue sarcoma. Ann Surg Oncol. 2008;15:2739-2748.
9. Singer S, Antonescu CR, Riedel E, et al. Histologic subtype and margin
of resection predict pattern of recurrence and survival for retroperitoneal
liposarcoma. Ann Surg. 2003;238:358-370, discussion 370-371.
10. Barretina J, Taylor BS, Banerji S, et al. Subtype-specifıc genomic alterations
defıne new targets for soft-tissue sarcoma therapy. Nat Genet.
2010;42:715-721.
11. Jones RL, Fisher C, Al-Muderis O, et al. Differential sensitivity of liposarcoma
subtypes to chemotherapy. Eur J Cancer. 2005;41:2853-2860.
12. Schwartz GK, LoRusso PM, Dickson MA, et al. Phase I study of PD
0332991, a cyclin-dependent kinase inhibitor, administered in 3-week
cycles (Schedule 2/1). Br J Cancer. 2011;104:1862-1868.
13. Dickson MA, Tap WD, Keohan ML, et al. Phase II trial of the CDK4
inhibitor PD0332991 in patients with advanced CDK4-amplifıed welldifferentiated
or dedifferentiated liposarcoma. J Clin Oncol. 2013;31:
2024-2028.
14. Dickson MA, Tap WD, Keohan ML, et al. Phase II trial of the CDK4
inhibitor PD0332991 in patients with advanced CDK4-amplifıed liposarcoma.
J Clin Oncol. 2013;31 (suppl; abstr 10512).
15. Patnaik A, Rosen LS, Tolaney SM, et al. Clinical activity of LY2835219, a
novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with
metastatic breast cancer. Paper presented at: American Association of Cancer
Research Annual Meeting; April 2014; San Diego, CA (abstr CT232).
16. Infante JR, Shapiro GI, Witteveen JF, et al. Phase 1 multicenter, open
label, dose-escalation study of LEE011, an oral inhibitor of cyclindependent
kinase 4/6, in patients with advanced solid tumors or lymphomas.
Mol Cancer Ther. 2013;12 (11 suppl; abstr A276).
17. Kovatcheva M, Liu DD, Dickson MA, et al. MDM2 turnover and expression
of ATRX determine the choice between quiescence and senescence
in response to CDK4 inhibition. Oncotarget. 2015. In press.
18. Leach FS, Tokino T, Meltzer P, et al. p53 mutation and MDM2 amplifıcation
in human soft tissue sarcomas. Cancer Res. 1993;53:2231-2234.
19. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53
pathway by small-molecule antagonists of MDM2. Science. 2004;303:
844-848.
20. Ray-Coquard I, Blay JY, Italiano A, et al. Effect of the MDM2 antagonist
RG7112 on the P53 pathway in patients with MDM2-amplifıed, welldifferentiated
or dedifferentiated liposarcoma: an exploratory proof-ofmechanism
study. Lancet Oncol. 2012;13:1133-1140.
21. Iancu-Rubin C, Mosoyan G, Glenn K, et al. Activation of p53 by the
MDM2 inhibitor RG7112 impairs thrombopoiesis. Exp Hematol. 2014;
42:137-145.
22. Wang S, Sun W, Zhao Y, et al. SAR405838: an optimized inhibitor of
MDM2-p53 interaction that induces complete and durable tumor regression.
Cancer Res. 2014;74:5855-5865.
23. de Weger V, Lolkema MP, Dickson M, et al. A fırst-in-human (FIH)
safety and pharmacological study of SAR405838, a novel HDM2 antagonist,
in patients with solid malignancies. Eur J Cancer. 2014;50:121-122
(6 suppl; abstr 378).
24. Grosso F, Jones RL, Demetri GD, et al. Effıcacy of trabectedin
(ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective
study. Lancet Oncol. 2007;8:595-602.
25. Kilpatrick SE, Doyon J, Choong PF, et al. The clinicopathologic spectrum
of myxoid and round cell liposarcoma. A study of 95 cases. Cancer.
1996;77:1450-1458.
26. Antonescu CR, Tschernyavsky SJ, Decuseara R, et al. Prognostic impact
of P53 status, TLS-CHOP fusion transcript structure, and histological
grade in myxoid liposarcoma: a molecular and clinicopathologic study
of 82 cases. Clin Cancer Res. 2001;7:3977-3987.
27. Spillane AJ, Fisher C, Thomas JM. Myxoid liposarcoma—the frequency
and the natural history of nonpulmonary soft tissue metastases. Ann
Surg Oncol. 1999;6:389-394.
28. Mitelman F. Catalog of Chromosome Aberrations in Cancer, 5th ed. New
York, NY: Wiley-Liss, Inc.; 1994.
29. Antonescu CR, Tschernyavsky SJ, Decuseara R, et al. Prognostic impact
of P53 status, TLS-CHOP fusion transcript structure, and histological
grade in myxoid liposarcoma: a molecular and clinicopathologic study
of 82 cases. Clin Cancer Res. 2001; 7:3977-3987.
30. Fiore M, Grosso F, Lo Vullo S, et al. Myxoid/round cell and pleomorphic
liposarcomas: prognostic factors and survival in a series of patients
treated at a single institution. Cancer. 2007;109:2522-2531.
31. Di Giandomenico S, Frapolli R, Bello E, et al. Mode of action of trabectedin
in myxoid liposarcomas. Oncogene. 2014;33:5201-5210.
32. Mantovani A, Sozzani S, Locati M, et al. Macrophage polarization:
tumor-associated macrophages as a paradigm for polarized M2 mononuclear
phagocytes. Trends Immunol. 2002;23:549-555.
33. Pollard JW. Tumour-educated macrophages promote tumour progression
and metastasis. Nat Rev Cancer. 2004;4:71-78.
34. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression
and metastasis. Cell. 2010;141:39-51.
35. Allavena P, Mantovani A. Immunology in the clinic review series; focus on
cancer: tumour-associated macrophages: undisputed stars of the inflammatory
tumour microenvironment. Clin Exp Immunol. 2012;167:195-205.
36. Roylance R, Seddon B, McTiernan A, et al. Experience of the use of trabectedin
(ET-743, Yondelis) in 21 patients with pre-treated advanced sarcoma
from a single centre. Clin Oncol (R Coll Radiol). 2007;19:572-576.
37. Azumi N, Curtis J, Kempson RL, et al. Atypical and malignant neoplasms
showing lipomatous differentiation. A study of 111 cases. Am J
Surg Pathol. 1987;11:161-183.
38. Gebhard S, Coindre JM, Michels JJ, et al. Pleomorphic liposarcoma:
clinicopathologic, immunohistochemical, and follow-up analysis of 63
cases: a study from the French Federation of Cancer Centers Sarcoma
Group. Am J Surg Pathol. 2002;26:601-616.
39. Enzinger FM, Weiss SW. Liposarcoma. In Soft Tissue Tumors, 3rd ed. St.
Louis, MO: Mosby, 1995;431-466.
40. DownesKA,GoldblumJR,MontgomeryEA,etal.Pleomorphicliposarcoma:a
clinicopathologic analysis of 19 cases. Mod Pathol. 2001;14:179-184.
41. Italiano A, Garbay D, Cioffı A, et al. Advanced pleomorphic liposarcomas:
clinical outcome and impact of chemotherapy. Ann Oncol. 2012;
23:2205-2206.
42. Italiano A, Toulmonde M, Cioffı A, et al. Advanced well-differentiated/
dedifferentiated liposarcomas: role of chemotherapy and survival. Ann
Oncol. 2012;23:1601-1607.
218 2015 ASCO EDUCATIONAL BOOK | asco.org/edbook